ONWARD Medical: One-Year Study Shows Sustained Benefits of ARC-EX Therapy

ONWARD Medical N.V. (Euronext: ONWD), a pioneering medical technology company, has announced the publication of positive results from the Pathfinder2 Study in Neuromodulation: Technology at Neural Interface. The study, conducted over one year, demonstrates the long-term benefits and safety of ONWARD's ARC-EX Therapy combined with activity-based rehabilitation for people with spinal cord injury (SCI) in community-based rehabilitation centers.



The Pathfinder2 Study, sponsored by UK-based Spinal Research and independently conducted by Neurokinex, enrolled 10 participants with chronic cervical or thoracic SCI. The study found that participants experienced gains in upper body strength, trunk control, and balance throughout the one-year treatment period, with no indication of plateau in therapeutic benefit. Some participants also improved lower body movement and enhanced hand and arm strength, especially in grip and dexterity.



The study's long duration and positive results validate that ARC-EX Therapy can be safely and effectively delivered in community settings, making it more accessible to a broader range of SCI patients. The findings also reinforce the long-term benefits of continued access to ARC-EX Therapy and suggest further gains may be achievable with extended treatment.

"These results demonstrate the importance of sustained access to ARC-EX Therapy," said Dave Marver, CEO of ONWARD Medical. "Congratulations to the team at Neurokinex for showing ARC-EX Therapy can help people with SCI drive functional recovery without plateau during a one-year treatment period."

The study's community-based rehabilitation setting offers several advantages for the real-world applicability and accessibility of ARC-EX Therapy, including a more familiar and accessible environment, greater flexibility and personalization, lower costs, and the potential for wider adoption in rehabilitation centers.

ONWARD Medical is developing a pipeline of technologies, including its investigational implantable ARC-IM System and its investigational ARC-BCI System, an implanted platform that uses a brain-computer interface (BCI) powered by artificial intelligence (AI). The company plans to seek CE Mark certification to commercialize the ARC-EX System in Europe in 2025.

In conclusion, the Pathfinder2 Study's one-year duration and positive results highlight the long-term benefits and safety of ARC-EX Therapy, validating its use in community-based rehabilitation settings and paving the way for wider adoption in the treatment of SCI. As ONWARD Medical continues to develop its pipeline of innovative technologies, investors can expect the company to maintain its leadership in the medical technology sector.